mbiomics GmbH cashes in €13m in Series A financing
Munich-based microbiome therapeutics specialist mbiomics GmbH has raised €13m in the first closing of Series A round led by MIG Capital.
High-Tech Gründerfonds (HTGF) and the state bank Bayern Kapital joined the funding round together with private seed investors.The start-up company has a platform to identify disease-relevant changes in the gut microbiome, which are associated with chronic inflammatory diseases such as inflammatory bowel disease (IBD), cancer or multiple sclerosis.
According to Dr Laura Figulla, co-founder and CEO of mbiomics, the Series A financing will enable us to build our platform, accelerate the identification of our first lead drug candidates, and speed up the research efforts towards clinical validation. The companys platform provides a better understanding of the interactions between the gut microbiome and the host, allowing mbiomics to design microbial consortia that can be delivered to patients as precision therapies.
mbiomics will use the proceeds to embark on strategic partnerships, significantly expand their Munich laboratory facilities and R&D teams in Germany, and potentially increase US activities. According to Dr Johannes Woehrstein, co-founder and CTO, proof-of-concept for the companys analytics platform has already been established, which allows understanding microbiome modulation and designing effective microbiome therapies.
